Answer
Rifampicin is contraindicated with Prezista boosted with ritonavir or cobicistat because its strong CYP3A induction is expected to reduce plasma concentrations of darunavir, ritonavir and cobicistat, potentially causing loss of therapeutic effect and development of resistance.
Sources for this answer
- PREZISTA 100 mg/ml oral suspensionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.3 Contraindications · Version 21Document updated
Sources checked